Cargando…
Management of invasive aspergillosis in patients with COPD: Rational use of voriconazole
Invasive pulmonary aspergillosis (IPA) is an important cause of mortality in patients with hematologic malignancies. The reported incidence of IPA in the context of chronic obstructive pulmonary disease (COPD) seems to increase. Approximately 1%–2% of overall fatal cases of IPA occur in COPD patient...
Autores principales: | Ader, Florence, Bienvenu, Anne-Lise, Rammaert, Blandine, Nseir, Saad |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722867/ https://www.ncbi.nlm.nih.gov/pubmed/19684861 |
Ejemplares similares
-
Voriconazole-refractory invasive aspergillosis
por: Park, Se Yoon, et al.
Publicado: (2017) -
Putative invasive pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary disease: a matched cohort study
por: Delsuc, Claire, et al.
Publicado: (2015) -
Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis-review of the literature
por: Sandherr, M, et al.
Publicado: (2011) -
Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature
por: Karthaus, M
Publicado: (2011) -
Economic considerations in the treatment of invasive aspergillosis: a review of voriconazole pharmacoeconomic studies
por: Krueger, Kem P, et al.
Publicado: (2009)